Eczema

• Clinically proven 52% reduction in eczema symptoms compared to 17% placebo improvement

• Significantly reduces Staphylococcus bacteria linked to eczema severity through gut-skin axis modulation

• Maintains 100% colonization at 16 weeks for sustained therapeutic benefits

• L-92 probiotic strain achieved statistically significant eczema severity reductions in clinical trials with infants and toddlers

• Reduces key inflammatory markers including TARC and total IgE that drive allergic skin inflammation

• Shifts immune response away from Th2-driven allergic reactions toward regulated, tolerogenic profiles